Alexis E Horace1, Negar Golchin2, Elia M Pestana Knight3, Neal V Dawson4,5, Xuan Ma6, James A Feinstein7, Hannah K Johnson6, Lawrence Kleinman8, Paul M Bakaki6. 1. College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA. Horace@ulm.edu. 2. School of Pharmacy, University of Washington, Seattle, WA, USA. 3. Epilepsy Center/Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. 4. Center for Health Care Research and Policy, MetroHealth, Cleveland, OH, USA. 5. Department of Medicine, MetroHealth Medical Center, Cleveland, OH, USA. 6. Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA. 7. Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA. 8. Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA.
Abstract
PURPOSE: The purpose of this study is to describe medications most commonly studied in pediatric polypharmacy research by pharmacologic classes and disease using a scoping review methodology. METHODS: A search of electronic databases was conducted in July 2019 that included Ovid Medline, PubMed, Elsevier Embase, and EBSCO CINAHL. Primary observational studies were selected if they evaluated polypharmacy as an aim, outcome, predictor, or covariate in children 0-21 years of age. Studies not differentiating between adults and children or those not written in English were excluded. Study characteristics, pharmacologic categories, medication classes, and medications were extracted from the included studies. RESULTS: The search identified 8790 titles and after de-duplicating and full-text screening, 414 studies were extracted for the primary data. Regarding global pharmacologic categories, central nervous system (CNS) agents were most studied (n = 185, 44.9%). The most reported pharmacologic category was the anticonvulsants (n = 250, 60.4%), with valproic acid (n = 129), carbamazepine (n = 123), phenobarbital (n = 87), and phenytoin (n = 83) being the medications most commonly studied. In studies that reported medication classes (n = 105), serotonin reuptake inhibitors (n = 32, 30.5%), CNS stimulants (n = 30, 28.6%), and mood stabilizers (n = 27, 25.7%) were the most studied medication classes. CONCLUSION: While characterizing the literature on pediatric polypharmacy in terms of the types of medication studied, we further identified substantive gaps within this literature outside of epilepsy and psychiatric disorders. Medications frequently identified in use of polypharmacy for treatment of epilepsy and psychiatric disorders reveal opportunities for enhanced medication management in pediatric patients.
PURPOSE: The purpose of this study is to describe medications most commonly studied in pediatric polypharmacy research by pharmacologic classes and disease using a scoping review methodology. METHODS: A search of electronic databases was conducted in July 2019 that included Ovid Medline, PubMed, Elsevier Embase, and EBSCO CINAHL. Primary observational studies were selected if they evaluated polypharmacy as an aim, outcome, predictor, or covariate in children 0-21 years of age. Studies not differentiating between adults and children or those not written in English were excluded. Study characteristics, pharmacologic categories, medication classes, and medications were extracted from the included studies. RESULTS: The search identified 8790 titles and after de-duplicating and full-text screening, 414 studies were extracted for the primary data. Regarding global pharmacologic categories, central nervous system (CNS) agents were most studied (n = 185, 44.9%). The most reported pharmacologic category was the anticonvulsants (n = 250, 60.4%), with valproic acid (n = 129), carbamazepine (n = 123), phenobarbital (n = 87), and phenytoin (n = 83) being the medications most commonly studied. In studies that reported medication classes (n = 105), serotonin reuptake inhibitors (n = 32, 30.5%), CNS stimulants (n = 30, 28.6%), and mood stabilizers (n = 27, 25.7%) were the most studied medication classes. CONCLUSION: While characterizing the literature on pediatric polypharmacy in terms of the types of medication studied, we further identified substantive gaps within this literature outside of epilepsy and psychiatric disorders. Medications frequently identified in use of polypharmacy for treatment of epilepsy and psychiatric disorders reveal opportunities for enhanced medication management in pediatric patients.
Authors: Asia N Rashed; Lynda Wilton; Charles C H Lo; Benjamin Y S Kwong; Suzanne Leung; Ian C K Wong Journal: Br J Clin Pharmacol Date: 2014-05 Impact factor: 4.335
Authors: Rene Soria Saucedo; Xinyue Liu; Juan Manuel Hincapie-Castillo; Daniel Zambrano; Regina Bussing; Almut G Winterstein Journal: Psychiatr Serv Date: 2018-06-08 Impact factor: 3.084
Authors: Joseph F Goldberg; John O Brooks; Keiko Kurita; Jennifer C Hoblyn; S Nassir Ghaemi; Roy H Perlis; David J Miklowitz; Terence A Ketter; Gary S Sachs; Michael E Thase Journal: J Clin Psychiatry Date: 2009-02-10 Impact factor: 4.384
Authors: Divya Hoon; Matthew T Taylor; Pooja Kapadia; Tobias Gerhard; Brian L Strom; Daniel B Horton Journal: Pediatrics Date: 2019-09-16 Impact factor: 7.124
Authors: Rafia S Rasu; Mohammad Iqbal; Sma Hanifi; Ariful Moula; Shahidul Hoque; Sabrina Rasheed; Abbas Bhuiya Journal: Clinicoecon Outcomes Res Date: 2014-12-03
Authors: Mai T Pham; Andrijana Rajić; Judy D Greig; Jan M Sargeant; Andrew Papadopoulos; Scott A McEwen Journal: Res Synth Methods Date: 2014-07-24 Impact factor: 5.273
Authors: Luyu Xie; Andrew Gelfand; Caitlin C Murphy; M Sunil Mathew; Folefac Atem; George L Delclos; Sarah Messiah Journal: BMJ Open Date: 2022-10-13 Impact factor: 3.006